Clinical Feed

Piecing Together the Adrenal Puzzle: CAI Score and Postoperative Testing

Overview of studies highlighting CAI score for central adrenal insufficiency diagnosis, early post-adrenalectomy testing, and considerations for rare adrenal pathologies.

GIST

Four Studies that Can Improve Patient Outcomes Since April is Adrenal Disease Awareness Month, Endocrine News is highlighting recent studies that shed light on important advances and insights in the field. These studies, all published in Endocrine Society journals, show how improved diagnostic accuracy, postoperative management, and a better understanding of rare adrenal pathologies offer clinicians tools that could improve patient outcomes. At a Glance • The CAI score improves diagnostic accuracy in ambiguous cases of suspected central adrenal insufficiency (CAI) by integrating morning serum cortisol with key clinical parameters and can help guide treatment decisions. • Two-pronged testing consisting of basal cortisol and cosyntropin levels initiated as early as four weeks post-adrenalectomy can identify patients with adrenal insufficiency, guide glucocorticoid treatment, and obviate unnecessary glucocorticoids. • Although typically benign and nonsecretory, adrenal ganglioneuromas (AGNs) can rarely exhibit secretory properties that mimic other adrenal pathologies, making definitive histopathologic assessment essential; in cases of ACTH-dependent hypercortisolism with an adrenal lesion, secretory AGN should remain on the differential.

Clinical Editorial

Section 1: Framework for Interpreting Adrenal Pathophysiology in Contemporary Practice - The collection of studies and case reports highlights a spectrum of adrenal conditions and their diagnostic challenges, spanning diagnostic accuracy improvements, postoperative management considerations, and recognition of rare or deceptively benign pathologies that can present with clinically significant hormonal activity. - The overarching theme is that straightforward laboratory thresholds or single-test judgments may be insufficient in isolation. Integrated assessments that combine biochemical data, clinical features, imaging, and, when available, post-surgical trajectories are emphasized as more informative for guiding subsequent steps in workup, management, and follow-up. - The embedded narrative across the reports acknowledges the inherent variability in adrenal disease manifestations, including central adrenal insufficiency (CAI), post-adrenalectomy adrenal insufficiency, ACTH-dependent and ACTH-independent hypercortisolism, and rare adrenocortical neoplasms associated with MEN1. The material also underscores the ongoing need for standardization, external validation of novel tools, and longitudinal data to refine practice. Section 2: Advances in Diagnostic Stratification for Central Adrenal Insufficiency - Study focus and objective: - A predictive scoring system, named the CAI score, was developed to improve diagnostic accuracy in cases where morning cortisol and clinical context yield ambiguous impressions about central adrenal insufficiency (CAI). The intention was to provide a more nuanced risk stratification to determine the necessity of dynamic testing. - Design and population: - The analysis was a retrospective single-center study conducted at a Riyadh tertiary referral center, enrolling 341 adults with suspected CAI and indeterminate morning cortisol levels. The short Synacthen test (SST) served as the reference standard for CAI diagnosis. - Components and methodological approach: - The CAI score integrates morning cortisol levels with additional variables: pituitary hormone deficits, tumor size, sex, and prior treatment history. A machine learning model underpins the scoring system, which is accessible via a web-based application. - The investigators deliberately broadened the traditional gray-zone range for morning cortisol. Rather than the conventional 3–15 µg/dL span, they modeled the range from 4 to 18 µg/dL to reflect real-world lab variability and to capture differentiated risk as cortisol levels vary within that interval. - Key findings and interpretation: - The CAI score demonstrated superior diagnostic accuracy compared with using morning cortisol alone, indicating that incorporating pituitary function status, imaging-related features, and patient history provides a more robust assessment than relying on cortisol concentration in isolation. - A striking finding was the strong predictive value of coexisting pituitary hormone deficits. Specifically, having three or more additional hormone deficits emerged as a powerful predictor of CAI, with an odds ratio exceeding 35, underscoring that CAI commonly coexists with broader pituitary dysfunction. - Tumor size, while contributing to risk, did not carry as much predictive weight as the array of hormonal deficits, suggesting that functional impact on the surrounding pituitary tissue is more informative than tumor dimensions alone. - Practical implications and limitations: - The CAI score is offered as a decision-support tool intended to guide clinicians in determining whether to pursue dynamic testing in ambiguous cases. It is not presented as a replacement for clinical judgment. - External validation across diverse patient populations and clinical settings remains necessary to gauge generalizability and real-world impact, including effects on testing utilization and cost. The authors acknowledge that broader validation and demonstration of workflow integration are prerequisites for widespread uptake. - The authors emphasize that AI-assisted tools should augment, not supplant, clinician expertise and judgment, given the complex regulatory and physiological milieu underlying pituitary-adrenal axes. - Contextual relevance: - The study addresses a recognized clinical challenge: balancing test efficiency with diagnostic safety in CAI evaluation. By integrating multi-domain data and employing an adaptable framework that accommodates lab variability, the CAI score aligns with contemporary moves toward data-driven, personalized decision-making in endocrinology. Section 3: Post-Adrenalectomy Adrenal Insufficiency: Refining Timing and Testing Strategy - Study focus and objective: - A multicenter retrospective evaluation sought to define the prevalence and duration of adrenal insufficiency after unilateral adrenalectomy performed for mild autonomous cortisol secretion (MACS), and to determine whether basal cortisol testing suffices or if cosyntropin stimulation testing adds actionable information. - Design and population: - The study included 281 MACS patients, predominantly female (80%), with a median age of 57, drawn from five U.S. institutions. The analysis compared two postoperative cortisol testing modalities: basal (basal cortisol) versus cosyntropin stimulation testing (CST). - Key findings: - Postoperative adrenal insufficiency developed in roughly half of the studied cohort, indicating that a substantial subset experiences HPA-axis suppression after unilateral adrenalectomy for MACS. - Discordance between basal cortisol and CST emerged in about 22% of patients, highlighting that reliance on a single test can misclassify a meaningful proportion of cases and that a CST may provide complementary or clarifying information in postoperative assessment. - Age surfaced as a strong inverse predictor of recovery trajectory, with younger patients showing more severe biochemical suppression and longer times to recovery, whereas older patients appeared to recover more quickly on average. The authors suggest that younger individuals might harbor more biochemically active or prolonged cortisol autonomy, contributing to deeper HPA suppression. - The severity of biochemical or clinical indices of suppression correlated with longer recovery durations; patients with milder biochemical disruption tended to recover in approximately three months, whereas those with more severe suppression required a longer timeframe (roughly four to fourteen months). - Practical implications and limitations: - The data support earlier and structured postoperative reassessment, with a suggestion to initiate follow-up cortisol testing around four to six weeks after surgery and to continue at regular intervals. This approach is proposed to minimize unnecessary prolonged glucocorticoid exposure and to facilitate timely, individualized management. - The study avoids endorsing universal empiric glucocorticoid therapy postoperatively, advocating instead for targeted treatment decisions guided by objective testing results and severity indices. - The findings emphasize that a single postoperative cortisol value should not be the sole determinant of management, given discordant testing results and the variability of recovery timelines. - The authors acknowledge limitations inherent to retrospective analyses, including potential selection biases and the need for prospective validation to confirm predictive factors and testing intervals across broader patient populations. - Unresolved questions and forward directions: - The authors discuss the challenge of preoperative risk stratification due to uncertainties around the duration of cortisol autonomy in MACS, given that disease duration is often uncertain and MACS may be detected incidentally. They note that while developing a preoperative risk score is conceptually feasible, it would not eliminate the necessity for postoperative biochemical assessment. - Ongoing prospective cohorts are described as essential to validate predictors of duration and recovery more rigorously, and to refine recovery trajectory models using longitudinal ACTH and cortisol data. The team also highlights the need to explore mechanistic explanations for age-related differences and to standardize postoperative testing protocols across centers. - Contextual relevance: - The study contributes to a practical framework for managing postoperative adrenal function, balancing the risks associated with glucocorticoid exposure against the potential for spontaneous recovery. It emphasizes that timing and modality of testing influence clinical decision-making and patient safety. Section 4: Hidden Players in Adrenal Pathology: Rare Presentations with Critical Lessons - ACTH-secreting adrenal ganglioneuroma and the diagnostic conundrum: - The first case report documents a rare instance of an ACTH-secreting pure adrenal ganglioneuroma (AGN) associated with Cushing syndrome, representing only the second documented example of ACTH production by a pure AGN. The patient presented with hypertension, an adrenal mass on the right, anxiety, and diaphoresis, with biochemical evidence of ACTH-dependent hypercortisolism. - Diagnostic workup initially suggested pheochromocytoma, given the clinical context; however, normal plasma metanephrines and absence of a pituitary cause on imaging redirected the investigative trajectory toward adrenal pathology. Surgical resection yielded a histopathologic diagnosis of pure AGN with ACTH immunostaining confirming ACTH production. - Postoperative outcomes included normalization of blood pressure without antihypertensives and normalization of urinary free cortisol, illustrating that secretory activity by AGNs, though rare, can be clinically impactful and reversible with surgical intervention. - Implications for differential diagnosis emphasize the need to consider ACTH-secreting AGN within the spectrum of ACTH-dependent hypercortisolism when evaluating an adrenal lesion, particularly in the setting of incongruent biochemical or imaging findings. This case reinforces the importance of definitive histopathologic assessment to establish diagnosis in this domain. - MEN1-associated aggressive adrenal neoplasm and familial implications: - A separate case describes a 49-year-old woman with a multi-systemic presentation compatible with MEN1: recurrent hypoglycemia with insulinoma, primary hyperparathyroidism, an ACTH-independent hypercortisolic adrenal mass, and a history of pituitary macroprolactinoma. Genetic testing confirmed a MEN1 mutation. - Pathology revealed mucinous adrenocortical carcinoma, denoting an aggressive adrenal neoplasm within the MEN1 spectrum. Despite surgical management (adrenalectomy and distal pancreatectomy), the patient succumbed to postoperative sepsis and septic shock, with Cushing syndrome contributing to increased susceptibility to infection. - The case underscores the severe potential for malignant transformation within MEN1-associated adrenal lesions and the complexity of coordinating care across endocrine, surgical, and infectious disease domains in the context of Cushing syndrome. - A key ancillary finding from this report was the identification of an MEN1 mutation in the patient’s son, who is now at elevated risk for future tumor development. The authors emphasize the value of genetic testing and familial screening for early detection and preventive strategies, which can influence surveillance planning and potentially improve outcomes. - Clinical takeaway from rare presentations: - These cases illustrate that adrenal lesions can be hormonally active even when typical histology or imaging might imply benign behavior. The potential for ACTH production by an adrenal ganglioneuroma expands the differential when confronted with ACTH-dependent hypercortisolism and an adrenal lesion. - In MEN1 contexts, the spectrum of pathology includes mucinous adrenocortical carcinoma, with implications for prognosis and familial risk management. The reports collectively advocate for comprehensive hormonal evaluation and consideration of genetic etiologies when clinical features suggest multisystem endocrine involvement. - The overarching message from these rare presentations is heightened vigilance: clinicians should maintain a broad differential diagnosis and rely on histopathologic confirmation to resolve diagnostic ambiguities. The reports also emphasize structured genetic counseling and testing as integral components of care in MEN1-associated adrenal disease. Section 5: Hormonal Syndromes with an Open-Ended Prognostic Horizon - MEN1-associated adrenocortical carcinoma and surveillance imperatives: - The case shared in the MEN1 context demonstrates that MEN1-related adrenal tumors may present with aggressive histology (mucinous adrenocortical carcinoma) and can impact survival, particularly when superimposed on Cushing syndrome and infectious complications. - Longitudinal considerations include familial risk stratification, with identification of MEN1 mutation carriers enabling earlier detection strategies. The narrative highlights that routine genetic testing and family screening in MEN1 can inform surveillance strategies and potentially alter outcomes by enabling earlier intervention. - Broader implications for practice: - Collectively, the cases remind clinicians that rare histologies can intersect with more common adrenal syndromes, and that a high index of suspicion is warranted even when initial data might steer thinking toward more common etiologies. - The evidence underscores that histopathology remains a gold standard for definitive diagnosis in complex adrenal lesions, particularly when clinical and biochemical findings point toward a diverse range of potential etiologies, including ACTH-dependent hypercortisolism from ectopic sources or primary adrenal neoplasia associated with genetic syndromes. - The familial dimension highlighted in MEN1 cases reinforces the value of cascade testing, counseling, and a proactive approach to monitoring asymptomatic mutation carriers to improve early detection and potential clinical outcomes. Section 6: Contextual Narratives: Prevalence, Burden, and Public Health Framing - Epidemiologic context: - The Endocrine Society’s Endocrine Facts and Figures provides baseline prevalence estimates: primary adrenal insufficiency ranges roughly from 40 to 100 cases per million in the United States; Cushing syndrome affects about eight individuals per million under age 65; Cushing disease occurs at about 2.3–2.7 per million per year; MEN1 has an estimated prevalence of 3 to 10 per 100,000. - Interpretive caveats: - While these figures situate adrenal disorders within a public health frame, the articles do not introduce new population prevalence estimates. They instead illustrate the clinical heterogeneity and the functional consequences of adrenal disturbances, emphasizing diagnostic precision and timely intervention as potential drivers of improved outcomes.

Original source: https://endocrinenews.endocrine.org/piecing-together-the-adrenal-puzzle/